Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. (Nasdaq: ACTU) is a clinical-stage biopharmaceutical company developing cancer therapies that inhibit glycogen synthase kinase-3 beta (GSK-3β). Its sole drug candidate, elraglusib, is an ATP-competitive small molecule licensed exclusively from the University of Illinois Chicago and… From the company’s description.
In fiscal 2025, Actuate Therapeutics, Inc. reported a net loss of $22.23M. Operations used $19.21M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Actuate Therapeutics, Inc. does
In the company’s own words
Actuate Therapeutics, Inc. (Nasdaq: ACTU) is a clinical-stage biopharmaceutical company developing cancer therapies that inhibit glycogen synthase kinase-3 beta (GSK-3β). Its sole drug candidate, elraglusib, is an ATP-competitive small molecule licensed exclusively from the University of Illinois Chicago and Northwestern University. The company is evaluating intravenous elraglusib, alone and with chemotherapy, in clinical studies, with its most advanced program targeting first-line metastatic pancreatic ductal adenocarcinoma; other areas of development include pediatric Ewing sarcoma and neuroblastoma. Actuate has also selected an oral tablet formulation for planned studies in adults with advanced cancers, including potential programs in melanoma, colorectal cancer and non-small cell lung cancer. The company’s development work is organized around two dosage forms—Elraglusib Injection and Elraglusib Oral Tablet—rather than reported business segments. More than 500 patients have received elraglusib in Phase 1 and Phase 2 studies. Actuate’s research also includes investigator-initiated trials with academic medical centers and a collaboration with Lantern Pharma to study elraglusib and identify potentially responsive patient subtypes. Its website is https://www.actuatetherapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FORT WORTH, TX
- Fiscal year end
- December
- CIK
- 1652935
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Actuate Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Actuate Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Actuate Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Actuate Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Actuate Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”